海南医学
海南醫學
해남의학
HAINAN MEDICAL JOURNAL
2014年
15期
2191-2192
,共2页
谢礼仁%潘卫兵%曾灿%朱斌%周建华
謝禮仁%潘衛兵%曾燦%硃斌%週建華
사례인%반위병%증찬%주빈%주건화
前列腺癌%细胞凋亡%免疫组织化学%肿瘤坏死因子相关凋亡诱导配体%受体
前列腺癌%細胞凋亡%免疫組織化學%腫瘤壞死因子相關凋亡誘導配體%受體
전렬선암%세포조망%면역조직화학%종류배사인자상관조망유도배체%수체
Prostate cancer%Apoptosis%Immunohistochemistry%Tumor necrosis factor-related apoptosis-in-ducing ligand%Receptor
目的:探讨前列腺癌组织中TRAIL受体的表达及意义。方法采用免疫组织化学方法检测45例前列腺癌组织及15例良性前列腺增生组织中DR4、DR5及DcR1受体的表达水平。结果高分化、中分化、低分化前列腺癌组织与前列腺增生组织比较DR4、DR5受体的表达水平差异均无统计学意义(P>0.05),但高分化、中分化、低分化前列腺癌组织中DcR1的表达水平均明显低于前列腺增生组织,其差异均有统计学意义(P<0.05),且DcR1的表达水平在高分化、中分化、低分化前列腺癌组织中依次降低,差异有统计学意义(P<0.05)。结论 TRAIL受体DcR1在前列腺癌的发生发展中可能发挥重要作用。
目的:探討前列腺癌組織中TRAIL受體的錶達及意義。方法採用免疫組織化學方法檢測45例前列腺癌組織及15例良性前列腺增生組織中DR4、DR5及DcR1受體的錶達水平。結果高分化、中分化、低分化前列腺癌組織與前列腺增生組織比較DR4、DR5受體的錶達水平差異均無統計學意義(P>0.05),但高分化、中分化、低分化前列腺癌組織中DcR1的錶達水平均明顯低于前列腺增生組織,其差異均有統計學意義(P<0.05),且DcR1的錶達水平在高分化、中分化、低分化前列腺癌組織中依次降低,差異有統計學意義(P<0.05)。結論 TRAIL受體DcR1在前列腺癌的髮生髮展中可能髮揮重要作用。
목적:탐토전렬선암조직중TRAIL수체적표체급의의。방법채용면역조직화학방법검측45례전렬선암조직급15례량성전렬선증생조직중DR4、DR5급DcR1수체적표체수평。결과고분화、중분화、저분화전렬선암조직여전렬선증생조직비교DR4、DR5수체적표체수평차이균무통계학의의(P>0.05),단고분화、중분화、저분화전렬선암조직중DcR1적표체수평균명현저우전렬선증생조직,기차이균유통계학의의(P<0.05),차DcR1적표체수평재고분화、중분화、저분화전렬선암조직중의차강저,차이유통계학의의(P<0.05)。결론 TRAIL수체DcR1재전렬선암적발생발전중가능발휘중요작용。
Objective To investigate the expression of TRAIL receptors in human prostate cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression levels of DR4, DR5 and DcR1 receptors in 45 cases of prostate cancer and 15 cases of benign prostatic hyperplasia. Results There were no significant differences in the expression levels of DR4 and DR5 receptor in well-differentiated, moderately differentiat-ed, poorly differentiated prostate cancer and benign prostatic hyperplasia (P>0.05). However, the expression levels of DcR1 in well-moderately differentiated, poorly differentiated prostate cancer tissue were significantly lower than that in benign prostatic hyperplasia (P<0.05). And the expression levels of DcR1 in well-differentiated, moderately differ-entiated, poorly differentiated prostate cancer tissues were gradually reduced (P<0.05). Conclusion TRAIL recep-tors DcR1 may play an important role in the development of prostate cancer.